Estrogen Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Estrogen Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery [Phase 3]
A Phase 3 clinical trial evaluating fulvestrant and/or anastrozole for postmenopausal patients with stage II-III estrogen receptor-positive,…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer [Phase 1, Phase 2]
Genentech is evaluating GDC-4198 alone and in combination with giredestrant versus abemaciclib plus giredestrant in locally advanced or meta…
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer
This clinical trial update describes an independent, external, blinded retrospective validation of an AI-based prognostic assay for ER-posit…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors [Phase 1, Phase 2]
IDEAYA Biosciences is conducting a Phase 1/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of IDE574 in adults wi…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer [Phase 3]
Phase 3 trial evaluating Palazestrant in combination with ribociclib as first-line therapy for ER+/HER2- advanced/metastatic breast cancer; …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Breast Cancer Evolution During Neoadjuvant Systemic Therapy
Update on a breast cancer neoadjuvant systemic therapy trial, currently recruiting and covering ER-positive, HER2-positive, and triple-negat…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer [Phase 2]
Phase 2 clinical trial updates show BRC-001, a cannabidiol plant extract, being studied to improve aromatase inhibitor-induced arthralgia in…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression [Phase 2]
A Phase 2 clinical trial examining the combination of fulvestrant, ipatasertib, and a CDK4/6 inhibitor in metastatic estrogen receptor-posit…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer [Phase 1]
This clinical trial update reports on Z-Endoxifen Hydrochloride being studied for estrogen receptor-positive breast cancer that is metastati…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial [Phase 2]
Phase 2 trial update evaluating the optimal Tamoxifen dose for breast cancer risk reduction in premenopausal women (RENAISSANCE). The study …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer [Phase 1]
This clinical trial update reports testing the addition of berzosertib to radiation therapy in patients with chemotherapy-resistant triple-n…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy [Phase 3]
Phase 3 clinical trial update for camizestrant in estrogen receptor–positive, HER2-negative early breast cancer after at least 2 years of ad…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
A clinical trial update describes ongoing evaluation of evidence-based chemotherapy use in endocrine-sensitive breast cancer. The study is c…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies [Phase 2]
A Phase 2 trial update from UNC Lineberger Comprehensive Cancer Center for biomarker-driven therapies in breast cancer, currently recruiting…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer [Phase 1, Phase 2]
Hoffmann-La Roche is conducting a Phase 1/2 study to evaluate the safety and efficacy of multiple treatment combinations in patients with es…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers [Phase 2]
Phase 2 clinical trial evaluating pre-operative Neratinib and Trastuzumab with endocrine therapy for ER-positive, HER2-positive breast cance…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer [NA]
Clinical trial update indicates ongoing recruitment for Signatera-guided CDK4/6 inhibitor therapy in breast cancer.
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer [Phase 1]
This Phase 1 trial, sponsored by Genentech, evaluates the safety, pharmacokinetics, and activity of GDC-0587 as a monotherapy and in combina…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study evaluating ribociclib (LEE011) and alpelisib (BYL719) in combination with letrozole for…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery [Phase 2]
A Phase 2 clinical trial sponsored by Mayo Clinic is evaluating turkey tail mushroom extract in post-menopausal women with estrogen receptor…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer [Phase 2]
Phase II randomized trial comparing baby exemestane to baby tamoxifen in post-menopausal women at high risk for breast cancer (not yet recru…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
A Mayo Clinic-sponsored trial is evaluating interventions to improve skin appearance and quality of life for breast cancer survivors on arom…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Circulating Tumor DNA [Phase 2]
A Phase 2 clinical trial update indicates a study evaluating circulating tumor DNA in estrogen receptor-positive breast cancer is currently …
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.
Clinical trial update indicating ongoing recruitment to study the prevalence of treatment-induced mutations in metastatic estrogen receptor-…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer [Phase 3]
Phase 3 trial evaluating Palazestrant (OP-1250) versus standard of care for ER-positive, HER2-negative advanced/metastatic breast cancer is …